Welcome to chemicalbook!
400-158-6606

Get started now

or
My Account
Buyers
Inquiry management
Suppliers
Quotation management
Request for quotation
My ChemicalBook
My ChemicalBook
Postion:Product Catalog >API>Circulatory system drugs>Anti-atherosclerotic Drugs>Ezetimibe

Ezetimibe

US $1.00 / 1KG

Min. Order: 1G
Purity: 98%
Cas No.: 163222-33-1
Supply Ability: 100KG
  • 1KG

Overview

Product Name: Ezetimibe
CAS No.: 163222-33-1
EC-No.:
Min. Order: 1G
Purity: 98%
Supply Ability: 100KG
Release date: 2019/07/06
Product Advantage

AD68

Ezetimibe Basic information
Description Indications and Usage Mechanisms of Action References
Product Name: Ezetimibe
Synonyms: (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one;Ticagrelor and its interMediate;Ezetimibe 1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy-propyl]-4-(4-hydroxyphenyl)-azetidin-2-one;Ezatimibe;zetia/vytorin;SCH 60969;Ezetimibe, >=99%;(3R,4S)-1-(4-Fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azeti
CAS: 163222-33-1
MF: C24H21F2NO3
MW: 409.43
EINECS: 1308068-626-2
Product Categories: Final material;API;Isotope;CEDAX;Cardiovascular APIs;Ezetimibe;All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
Mol File: 163222-33-1.mol
Ezetimibe Structure
 
Ezetimibe Chemical Properties
Melting point  164-166°C
alpha  D22 -33.9° (c = 3 in methanol)
storage temp.  -20?C Freezer
CAS DataBase Reference 163222-33-1(CAS DataBase Reference)
 
Safety Information
Risk Statements  36/37/38
Safety Statements  26-36-24/25
MSDS Information
 
 
Ezetimibe Usage And Synthesis
Description Ezetimibe is ananti-hyperlipidemic drug used for lowering the plasma cholesterol levels. It is indicated as an adjunctive therapy to diet for the reduction of high-level total-C, LDL-C, and ApoB in patients suffering primary (heterozygous familial and non-familial) hypercholesterolemia. It is also used in combination therapy with HMG-CoA reductase inhibitors.Ezetimibe does not inhibit the cholesterol synthesis in the liver, or increase bile acid excretion.It takes effect throughacting at the brush border of the small intestine and inhibiting the absorption of cholesterol, further leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of blood cholesterol.
Indications and Usage Ezetimibe is a new form of selective cholesterol absorption inhibitor developed in a collaboration between Schering-Plough Co. and Merck Co. This drug is the first cholesterol absorption selective inhibitor to be approved for sale by the American FDA. Its commercial name is Ezetrol.
This drug can be used alone or in combination with HMG-CoA reductase inhibitors (statins) to treat primary (heterozygous familial and non-familial) hypercholesterolemia, homozygous familial hypercholesterolemia (HoFH), homozygous viremia (or phytosterolemia).
Mechanisms of Action Ezetimibe’s mechanisms of action are different from those of other lipid-lowering drugs (such as statins, cholic acid chelating agents, phenoxy acid derivatives, and plant sterols). This drug binds with the surface proteins on the brush border membrane vesicles of the small intestine (relative molecular mass 145x10^3) to inhibit the small intestine’s absorption of cholesterol in food and bile, thus decreasing the cholesterol content in serum and the liver. Ezetimibe is different from bile acid sequestrants because it does not affect the absorption of cholesterol esters, other steroids (such as bezoar and cholic acid), three triacylglycerol, and fat-soluble vitamins. Its effects are unrelated to whether or not acetyl coenzyme A- cholesterol acetyltransferase (ACAT) is inhibited or whether or not the LDL receptor (scavenger receptor) is expressed. After Ezetimibe is absorbed and binds with glucuronic acid in the liver, it undergoes enterohepatic circulation and almost exclusively targets small intestine mucosa cells.
References https://en.wikipedia.org/wiki/Ezetimibe
https://pubchem.ncbi.nlm.nih.gov/compound/Ezetimibe#section=Top
https://www.drugbank.ca/drugs/DB00973
Davidson, Michael H, et al. "Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia ☆." Journal of the American College of Cardiology 40.12(2002):2125.
Sudhop, T, et al. "Inhibition of intestinal cholesterol absorption by ezetimibe in humans. " Circulation 106.15(2002):1943-8.
Chemical Properties White Solid
Uses An antihyperlipoproteinemic. A Cholesterol absorption inhibitor
Uses antibacterial
Uses A cholesterol transport inhibitor that binds to NPC1L1
Uses For use as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hypercholesterolemia.

Country:China

Business model: Trader,Manufacturer

CB index: 58

Audit supplier

  • Telephone: +86-371-86658258
  • Fax:
  • Mobile: 13203830695
  • Address: No 70, Dianchang Road, Zhengzhou City, China

You may like

1-Methylcyclohexanol

1-Methylcyclohexanol

CAS:590-67-0

USD $ 240.00 / 1KG

UV 312

UV 312

CAS:23949-66-8

USD $ 750.00 / 25KG

Nitroethylene

Nitroethylene

CAS:3638-64-0

USD $ 2.00/ G-10.00 / KG

	4-(4-Methoxyphenyl)butyric acid

4-(4-Methoxyphenyl)butyric acid

CAS:4521-28-2

USD $ 2.00/ KG-10.00 / KG

	4-(P-TOLYL)BUTYRIC ACID

4-(P-TOLYL)BUTYRIC ACID

CAS:4521-22-6

USD $ 2.00/ KG-10.00 / KG